What changedRaised $315M in Series D funding, led by Ally Bridge Group and Alpha Wave.
The company said the funding supports advance ADVC001, its novel Lead-212 PSMA-targeted radioligand therapy for metastatic prostate cancer toward Phase 3 development, expand vertically integrated radiopharmaceutical platform and manufacturing infrastructure, and accelerate its growing pipeline of targeted alpha therapies Led by CEO Philina Lee, AdvanCell is a clinical-stage radiopharmaceutical company developing new targeted alpha the.
Likely next AfterRaise intelligenceNew market entryFirst local hires in the new marketLocal entity and legal setup
Where help may be relevant AfterRaise intelligenceCommercial leadershipOperations hiringGo-to-market partnershipsMarket-entry advisersLocal employment infrastructure
Approach preferences not yet specified